Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.

Guan J, Fransson S, Siaw JTT, Treis D, Van den Eynden J, Chand D, Umapathy G, Svenberg P, Ruuth K, Wessman S, Shamikh A, Jacobsson H, Gordon L, Stenman J, Larsson E, Svensson PJ, Hansson M, Martinsson T, Kogner P, Palmer RH, Hallberg B.

Cold Spring Harb Mol Case Stud. 2018 Jun 15. pii: mcs.a002550. doi: 10.1101/mcs.a002550. [Epub ahead of print]

2.

Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.

Kock A, Larsson K, Bergqvist F, Eissler N, Elfman LHM, Raouf J, Korotkova M, Johnsen JI, Jakobsson PJ, Kogner P.

EBioMedicine. 2018 Jun;32:84-92. doi: 10.1016/j.ebiom.2018.05.008. Epub 2018 May 24.

3.

Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.

Georgantzi K, Sköldenberg EG, Stridsberg M, Kogner P, Jakobson Å, Janson ET, Christofferson RHB.

Pediatr Hematol Oncol. 2018 May 8:1-10. doi: 10.1080/08880018.2018.1464087. [Epub ahead of print]

PMID:
29737901
4.

Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis.

Mondal T, Juvvuna PK, Kirkeby A, Mitra S, Kosalai ST, Traxler L, Hertwig F, Wernig-Zorc S, Miranda C, Deland L, Volland R, Bartenhagen C, Bartsch D, Bandaru S, Engesser A, Subhash S, Martinsson T, Carén H, Akyürek LM, Kurian L, Kanduri M, Huarte M, Kogner P, Fischer M, Kanduri C.

Cancer Cell. 2018 Mar 12;33(3):417-434.e7. doi: 10.1016/j.ccell.2018.01.020.

PMID:
29533783
5.

Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE(2)-C neuroblastoma.

Hultman I, Haeggblom L, Rognmo I, Jansson Edqvist J, Blomberg E, Ali R, Phillips L, Sandstedt B, Kogner P, Shirazi Fard S, Ährlund-Richter L.

PLoS One. 2018 Jan 17;13(1):e0190970. doi: 10.1371/journal.pone.0190970. eCollection 2018.

6.

Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo.

Tümmler C, Snapkov I, Wickström M, Moens U, Ljungblad L, Maria Elfman LH, Winberg JO, Kogner P, Johnsen JI, Sveinbjørnsson B.

Oncotarget. 2017 Jul 27;8(56):95135-95151. doi: 10.18632/oncotarget.19619. eCollection 2017 Nov 10.

7.

Rho-associated kinase is a therapeutic target in neuroblastoma.

Dyberg C, Fransson S, Andonova T, Sveinbjörnsson B, Lännerholm-Palm J, Olsen TK, Forsberg D, Herlenius E, Martinsson T, Brodin B, Kogner P, Johnsen JI, Wickström M.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6603-E6612. doi: 10.1073/pnas.1706011114. Epub 2017 Jul 24.

8.

Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

Westerlund I, Shi Y, Toskas K, Fell SM, Li S, Surova O, Södersten E, Kogner P, Nyman U, Schlisio S, Holmberg J.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6137-E6146. doi: 10.1073/pnas.1700655114. Epub 2017 Jul 10.

9.

Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ-mediated transport of TRKA.

Fell SM, Li S, Wallis K, Kock A, Surova O, Rraklli V, Höfig CS, Li W, Mittag J, Henriksson MA, Kenchappa RS, Holmberg J, Kogner P, Schlisio S.

Genes Dev. 2017 May 15;31(10):1036-1053. doi: 10.1101/gad.297077.117.

10.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
11.

Improved Local Control by Extensive Surgery in High-Risk Neuroblastoma May Be Dependent on Adjuvant Radiotherapy.

Stenman J, Herold N, Svensson PJ, Kogner P.

J Clin Oncol. 2017 Jun 10;35(17):1965-1966. doi: 10.1200/JCO.2016.72.1175. Epub 2017 Apr 19. No abstract available.

PMID:
28422555
12.

Lithium protects hippocampal progenitors, cognitive performance and hypothalamus-pituitary function after irradiation to the juvenile rat brain.

Zhou K, Xie C, Wickström M, Dolga AM, Zhang Y, Li T, Xu Y, Culmsee C, Kogner P, Zhu C, Blomgren K.

Oncotarget. 2017 May 23;8(21):34111-34127. doi: 10.18632/oncotarget.16292.

13.

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D; SIOP Europe Neuroblastoma Group (SIOPEN).

Lancet Oncol. 2017 Apr;18(4):500-514. doi: 10.1016/S1470-2045(17)30070-0. Epub 2017 Mar 2.

PMID:
28259608
14.

Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade.

Eissler N, Mao Y, Brodin D, Reuterswärd P, Andersson Svahn H, Johnsen JI, Kiessling R, Kogner P.

Oncoimmunology. 2016 Sep 9;5(12):e1232222. doi: 10.1080/2162402X.2016.1232222. eCollection 2016.

15.

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T.

Nat Med. 2017 Feb;23(2):256-263. doi: 10.1038/nm.4265. Epub 2017 Jan 9.

PMID:
28067901
16.

Venetoclax in cancer therapy and potential effects on bone.

Zaman F, Kogner P, Sävendahl L.

Lancet Oncol. 2016 Aug;17(8):e319-e320. doi: 10.1016/S1470-2045(16)30228-5. No abstract available.

PMID:
27511157
17.

The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis.

Snapkov I, Öqvist CO, Figenschau Y, Kogner P, Johnsen JI, Sveinbjørnsson B.

BMC Cancer. 2016 Jul 18;16:490. doi: 10.1186/s12885-016-2545-1.

18.

Regulation of Nuclear Hormone Receptors by MYCN-Driven miRNAs Impacts Neural Differentiation and Survival in Neuroblastoma Patients.

Ribeiro D, Klarqvist MDR, Westermark UK, Oliynyk G, Dzieran J, Kock A, Savatier Banares C, Hertwig F, Johnsen JI, Fischer M, Kogner P, Lovén J, Arsenian Henriksson M.

Cell Rep. 2016 Jul 26;16(4):979-993. doi: 10.1016/j.celrep.2016.06.052. Epub 2016 Jul 7.

19.

Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma.

Dyberg C, Papachristou P, Haug BH, Lagercrantz H, Kogner P, Ringstedt T, Wickström M, Johnsen JI.

BMC Cancer. 2016 Mar 31;16:259. doi: 10.1186/s12885-016-2293-2.

20.

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R.

Clin Cancer Res. 2016 Aug 1;22(15):3849-59. doi: 10.1158/1078-0432.CCR-15-1912. Epub 2016 Mar 8.

21.

The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.

Li S, Fell SM, Surova O, Smedler E, Wallis K, Chen ZX, Hellman U, Johnsen JI, Martinsson T, Kenchappa RS, Uhlén P, Kogner P, Schlisio S.

Dev Cell. 2016 Jan 25;36(2):164-78. doi: 10.1016/j.devcel.2015.12.029.

22.

Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.

Fransson S, Östensson M, Djos A, Javanmardi N, Kogner P, Martinsson T.

Int J Oncol. 2016 Mar;48(3):1103-16. doi: 10.3892/ijo.2016.3349. Epub 2016 Jan 19.

PMID:
26794043
23.

Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors.

Olsson M, Beck S, Kogner P, Martinsson T, Carén H.

Epigenetics. 2016;11(1):74-84. doi: 10.1080/15592294.2016.1138195. Epub 2016 Jan 19.

24.

Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.

Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool M, Kogner P, Baryawno N, Johnsen JI.

Nat Commun. 2015 Nov 25;6:8904. doi: 10.1038/ncomms9904.

25.

COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.

Larsson K, Kock A, Idborg H, Arsenian Henriksson M, Martinsson T, Johnsen JI, Korotkova M, Kogner P, Jakobsson PJ.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8070-5. doi: 10.1073/pnas.1424355112. Epub 2015 Jun 15.

26.

The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation.

Pandey GK, Mitra S, Subhash S, Hertwig F, Kanduri M, Mishra K, Fransson S, Ganeshram A, Mondal T, Bandaru S, Ostensson M, Akyürek LM, Abrahamsson J, Pfeifer S, Larsson E, Shi L, Peng Z, Fischer M, Martinsson T, Hedborg F, Kogner P, Kanduri C.

Cancer Cell. 2014 Nov 10;26(5):722-37. doi: 10.1016/j.ccell.2014.09.014. Epub 2014 Nov 10.

27.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223. Epub 2014 Sep 23.

PMID:
25251827
28.

Emergence of new ALK mutations at relapse of neuroblastoma.

Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, Pierron G, Lapouble E, Combaret V, Speleman F, de Wilde B, Djos A, Ora I, Hedborg F, Träger C, Holmqvist BM, Abrahamsson J, Peuchmaur M, Michon J, Janoueix-Lerosey I, Kogner P, Delattre O, Martinsson T.

J Clin Oncol. 2014 Sep 1;32(25):2727-34. doi: 10.1200/JCO.2013.54.0674. Epub 2014 Jul 28.

PMID:
25071110
29.

Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.

Eriksson E, Wickström M, Perup LS, Johnsen JI, Eksborg S, Kogner P, Sävendahl L.

J Natl Cancer Inst. 2014 Mar;106(3):djt459. doi: 10.1093/jnci/djt459. Epub 2014 Mar 1.

PMID:
24586107
30.

RNA helicase A is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma.

Chen ZX, Wallis K, Fell SM, Sobrado VR, Hemmer MC, Ramsköld D, Hellman U, Sandberg R, Kenchappa RS, Martinson T, Johnsen JI, Kogner P, Schlisio S.

Cancer Discov. 2014 Apr;4(4):434-51. doi: 10.1158/2159-8290.CD-13-0362. Epub 2014 Jan 27.

31.

Tropism of the in situ growth from biopsies of childhood neuroectodermal tumors following transplantation into experimental teratoma.

Jamil S, Hultman I, Cedervall J, Ali RQ, Fuchs G, Gustavsson B, Asmundsson J, Sandstedt B, Kogner P, Ährlund-Richter L.

Int J Cancer. 2014 Apr 1;134(7):1630-7. doi: 10.1002/ijc.28498. Epub 2013 Oct 17.

32.

Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene.

Djos A, Fransson S, Kogner P, Martinsson T.

BMC Med Genet. 2013 Oct 2;14:102. doi: 10.1186/1471-2350-14-102.

33.

Neuroblastoma-related inflammation: May small doses of aspirin be suitable for small cancer patients?

Carlson LM, Kogner P.

Oncoimmunology. 2013 Jul 1;2(7):e24658. Epub 2013 Apr 30.

34.

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.

Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G.

Clin Cancer Res. 2013 Sep 15;19(18):5092-103. doi: 10.1158/1078-0432.CCR-12-2211. Epub 2013 Jul 17.

35.

Neuroblastoma cells injected into experimental mature teratoma reveal a tropism for embryonic loose mesenchyme.

Jamil S, Cedervall J, Hultman I, Ali R, Margaryan NV, Rasmuson A, Johnsen JI, Sveinbjörnsson B, Dalianis T, Kanter L, Orrego A, Strizzi L, Hendrix MJ, Sandstedt B, Kogner P, Ahrlund-Richter L.

Int J Oncol. 2013 Sep;43(3):831-8. doi: 10.3892/ijo.2013.2014. Epub 2013 Jul 12.

PMID:
23857308
36.

ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

Wilzén A, Krona C, Sveinbjörnsson B, Kristiansson E, Dalevi D, Øra I, De Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F.

Mol Cancer. 2013 Jul 8;12(1):70. doi: 10.1186/1476-4598-12-70.

37.

The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes.

Carlson LM, De Geer A, Sveinbjørnsson B, Orrego A, Martinsson T, Kogner P, Levitskaya J.

Oncoimmunology. 2013 Mar 1;2(3):e23618.

38.

MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.

Zirath H, Frenzel A, Oliynyk G, Segerström L, Westermark UK, Larsson K, Munksgaard Persson M, Hultenby K, Lehtiö J, Einvik C, Påhlman S, Kogner P, Jakobsson PJ, Henriksson MA.

Proc Natl Acad Sci U S A. 2013 Jun 18;110(25):10258-63. doi: 10.1073/pnas.1222404110. Epub 2013 Jun 3.

39.

Frequent detection of human cytomegalovirus in neuroblastoma: a novel therapeutic target?

Wolmer-Solberg N, Baryawno N, Rahbar A, Fuchs D, Odeberg J, Taher C, Wilhelmi V, Milosevic J, Mohammad AA, Martinsson T, Sveinbjörnsson B, Johnsen JI, Kogner P, Söderberg-Nauclér C.

Int J Cancer. 2013 Nov 15;133(10):2351-61. doi: 10.1002/ijc.28265. Epub 2013 Jul 13.

40.

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.

Cetinkaya C, Martinsson T, Sandgren J, Träger C, Kogner P, Dumanski J, Díaz de Ståhl T, Hedborg F.

BMC Cancer. 2013 May 9;13:231. doi: 10.1186/1471-2407-13-231.

41.

Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.

Fransson S, Kogner P, Martinsson T, Ejeskär K.

J Mol Signal. 2013 Apr 18;8(1):4. doi: 10.1186/1750-2187-8-4.

42.

Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis.

Pettersen I, Baryawno N, Abel F, Bakkelund WH, Zykova SN, Winberg JO, Moens U, Rasmuson A, Kogner P, Johnsen JI, Sveinbjörnsson B.

Int J Oncol. 2013 Apr;42(4):1239-48. doi: 10.3892/ijo.2013.1800. Epub 2013 Jan 29.

PMID:
23443741
43.

Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma.

Carlson LM, Rasmuson A, Idborg H, Segerström L, Jakobsson PJ, Sveinbjörnsson B, Kogner P.

Carcinogenesis. 2013 May;34(5):1081-8. doi: 10.1093/carcin/bgt009. Epub 2013 Jan 24.

PMID:
23349014
44.

Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.

Rasmuson A, Segerström L, Nethander M, Finnman J, Elfman LH, Javanmardi N, Nilsson S, Johnsen JI, Martinsson T, Kogner P.

PLoS One. 2012;7(12):e51297. doi: 10.1371/journal.pone.0051297. Epub 2012 Dec 17.

45.

Stage-dependent expression of PI3K/Akt‑pathway genes in neuroblastoma.

Fransson S, Abel F, Kogner P, Martinsson T, Ejeskär K.

Int J Oncol. 2013 Feb;42(2):609-16. doi: 10.3892/ijo.2012.1732. Epub 2012 Dec 12.

PMID:
23232578
46.

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.

Chand D, Yamazaki Y, Ruuth K, Schönherr C, Martinsson T, Kogner P, Attiyeh EF, Maris J, Morozova O, Marra MA, Ohira M, Nakagawara A, Sandström PE, Palmer RH, Hallberg B.

Dis Model Mech. 2013 Mar;6(2):373-82. doi: 10.1242/dmm.010348. Epub 2012 Oct 25.

47.

Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.

Kiss NB, Kogner P, Johnsen JI, Martinsson T, Larsson C, Geli J.

BMC Med Genet. 2012 Sep 17;13:83. doi: 10.1186/1471-2350-13-83.

48.

Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.

Wickström M, Dyberg C, Shimokawa T, Milosevic J, Baryawno N, Fuskevåg OM, Larsson R, Kogner P, Zaphiropoulos PG, Johnsen JI.

Int J Cancer. 2013 Apr 1;132(7):1516-24. doi: 10.1002/ijc.27820. Epub 2012 Oct 3.

49.

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Djos A, Martinsson T, Kogner P, Carén H.

Mol Cancer. 2012 Jun 13;11:40. doi: 10.1186/1476-4598-11-40.

50.

Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase.

Hiyoshi H, Abdelhady S, Segerström L, Sveinbjörnsson B, Nuriya M, Lundgren TK, Desfrere L, Miyakawa A, Yasui M, Kogner P, Johnsen JI, Andäng M, Uhlén P.

Br J Cancer. 2012 May 22;106(11):1807-15. doi: 10.1038/bjc.2012.159. Epub 2012 Apr 24.

Supplemental Content

Loading ...
Support Center